
















Page 1 of 2

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: <del>10827,528</del> 10/747,865							
LIST OF PRIOR ART CITED BY APPLICANT  (Use several sheets if necessary)				APPLICANT(S): Benjamin OSHLACK et al.									
				FILING DATE: December 29, 2003		GROUP: 1614							
U.S. PATENT DOCUMENTS													
*EXAMINER INITIAL		DOCUMENT NUMBER						DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	BA												
	BB												
	BC												
	BD												
	BE												
FOREIGN PATENT DOCUMENTS													
		DOCUMENT NUMBER						DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
												YES	NO
	BF												
	BG												
	BH												
	BI												
	BJ												
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)													
	BK												
	BL												
	BN												
	BO												
	BP												
	BQ												
JR	BR	Miaskowski et al., "Inhibition of Spinal Opioid Analgesia by Supraspinal Administration of Selective Opioid Antagonists", Brain Research (1992), 30:263-274.											
EXAMINER Jeffrey E. Russell				DATE CONSIDERED November 10, 2005									
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.													

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: <del>10/827,623</del> 10/747,865	
<b>LIST OF PRIOR ART CITED BY APPLICANT</b> (Use several sheets if necessary)				APPLICANT(S): Benjamin OSHLACK et al.			
				FILING DATE: December 29, 2003		GROUP: 1614	
<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	DA						
	DB						
	DC						
	DD						
	DE						
	DF						
	DG						
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
	DH						
	DI						
	DJ						
	DK						
	DL						
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
	DM	Alvarez-Fuentes, et al. "Effectiveness of Repeated Administration of a New Ora Naltrexone Controlled-Release System in Morphine Analgesia"; J. Pharm Pharmacol (2001), 53:1201-1205.					
	DN	Alvarez-Fuentes, et al., "Predinical Study of an Oral Controlled Release Naltrexone Complex in Mice"; J. Pharm Pharmacol (2000), 52:659-663.					
	DO	Archer, Sydney; "Historical Perspective on the Chemistry and Development of Naltrexone"; Naltrexone Research Monograph 28 (1980) p. 3-9.					
	DP	Baum et al., "The Impact of the Addition of Naloxone on the Use and Abuse of Pentazocine"; Public Health Reports (1987) Vol. 102, No. 4 p. 426-429.					
	DQ	Rapaka et al., "Discovery of Novel Opioid Medications"; NIDA Research Monograph 147 (1995) p. 55-83.					
	DR	Bloom et al., "Clinical Studies with Naloxone/Methadone in a Ratio of 1:20"; 5th National Conference on Methadone Treatment (1973) Vol 2, p. 1342-1349.					
EXAMINER  Jeffrey E. Russel				DATE CONSIDERED  November 10, 2005			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: <del>10/27/03</del> 10/7/03 865	
<b>LIST OF PRIOR ART CITED BY APPLICANT</b> (Use several sheets if necessary)				APPLICANT(S): Benjamin OSHLACK et al.			
				FILING DATE: December 29, 2003		GROUP: 1614	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	EA						
	EB						
	EC						
	ED						
	EE						
	EF						
	EG						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
	EH						
	EL						
	EJ						
	EK						
	EL						
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	EM	Briscoe et al., "Methoclocinnamox: Time Course of Changes in Affetnanil-Reinforced Rhesus Monkeys"; Psychopharmacology (2000) 148:393-399.					
	EN	Abstract of Bromm, et al., "A Sensitive Method to Evaluate Effects of Analgesics in Man"; Meth and Find Exptl Clin Pharmacol 5 (8) (1983) p. 545-551.					
	EO	Bullingham et al., "Clinical Pharamcokinetics of Narcotic Agonist-Antagonist Drugs"; Clinical Pharm (1983) 8: 332-343.					
	EP	Calimim, et al. "Effect of Naloxone on the Analgesic Activity of Methadone in a 1:10 Oral Combination"; Clin Pharmacol and There (1974) Vol. 15; No. 6 pp.556-564.					
	EQ	Caruso et al., "Methadone and Naloxone in Combination (Naldone®) for the Treatment if Heroin Addicts"; Bristol Laboratories, pp.1336-1341F (Not Data)					
	ER	Cherny, Nathan I., "Opioid Analgesics"; Drugs (1996) May:51 (5) pp. 713-737.					
	ES	Chiang, et al. "Clinical Evaluation of a Naltrexone Sustained-Release Preparation"; Drug and Alcohol Dependence (1985) 16, pp.1-8.					
EXAMINER <b>Jeffrey E. Russel</b>				DATE CONSIDERED <b>November 10, 2005</b>			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: <del>10/827,628</del> 10/777,865	
<b>LIST OF PRIOR ART CITED BY APPLICANT</b> (Use several sheets if necessary)				APPLICANT(S): Benjamin OSHLACK et al.			
				FILING DATE: December 29, 2003		GROUP: 1614	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	FA						
	FB						
	FC						
	FD						
	FE						
	FF						
	FG						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	FH						
	FI						
	FJ						
	FK						
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
jn	FL	Chiang et al., "Kinetics of a Naltrexone Sustained-Release Preparation"; Clin Pharmacol Thera (1984) Vol 36 No. 5, pp.704-708.					
je	FM	Comer et al., "Depot Naltrexone: Long-lasting Antagonism of the Effects Of Heroin un Humans"; Psychopharmacology (2002) 159, pp.351-360.					
jn	FN	Crabtree et al., "Review of Naltrexone, a long-acting Opiate Antagonist"; Clinical Pharmacy, Vol. 3 (1984) pp.273-280.					
jn	FO	Crain et al., "Antagonists of Excitatory Opioid Receptor Functions Enhance Morphine's Analgesic Potency and Attenuate Opioid Tolerance/dependence liability"; Dept. of Neuroscience, Albert Einstein College of Medicine Pain 82 (1999)pp.1-11.					
jn	FP	Crain et al., "Antagonists of Excitatory Opioid Receptor Functions Enhance Morphine's Analgesic Potency and Attenuate Opioid Tolerance/dependence liability"; Dept. of Neuroscience, Albert Einstein College of Medicine Pain 84 (2000) pp.121-131.					
jn	FQ	Fink et al., "naloxone in Heroin Dependence"; Clin Pharm and Thera. Vol 9, No. 5:pp.568-577 (1968)					
jn	FR	Fishman et al., "Disposition of Naloxone-7,8- <sup>3</sup> H in Normal & Narcotic Dependent Men"; J. Pharm. And Exper. Thera (1973)Vol 10 No. 2:pp.575-580.					
EXAMINER  Jeffrey E. Russel				DATE CONSIDERED  November 10, 2005			
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: <del>10/327,623</del> 10/747,865	
<b>LIST OF PRIOR ART CITED BY APPLICANT</b>  (Use several sheets if necessary)				APPLICANT(S): Benjamin OSHLACK et al.			
				FILING DATE: December 29, 2003		GROUP: 1614	
<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	GA						
	GB						
	GC						
	GD						
	GE						
	GF						
	GG						
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
	GH						
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
	GI	Fraser, Albert D., et al., "Clinical Toxicology of Drugs Used in the Treatment of Opiate Dependency"; Clinical Toxicology 1 (1990) Vol 10, No. 2; pp.375-386.					
	GJ	Freye et al., "Effects of Tramadol and Tildine/Naloxone on Oral-Caecal Transit & Pupillary Light Reflex"; Arzneim-Forsch/Drug Res. 50(1)(2000)pp. 24-30.					
	GK	Fudala, et al., "Effects of Buprenorphine asnd Naloxone in Morphine-Stabilized Opioid Addicts"; Drug and Alcohol Dependence 50 (1998) pp. 1-8.					
	GL	Fudala et al., "Human Pharmacology and Abuse Potential Of Nalmefene"; Clin Pharm and Thera (1991) Vol 49, 3, pp. 300-306.					
	GM	Gal et al., "Prolonged Blockade of Opioid Effect with Oral Nalmefene"; Clin Pharm and Thera (1986) pp. 537-542.					
	GN	Gerra et al., "Clonidine and Opiate Receptor Antagonists in the Treatment of Heroin Addiction"; J. Substance Abuse Treatment (1995) Vol 12, 1, pp. 35-41.					
	GO	Ghodse, et al., "Opioid analgesics and Narcotic Antagonists"; Side Effects of Drugs (2000) Annual 23, chpt 8 pp. 96-113.					
EXAMINER  <i>Jeffrey E. Russel</i>				DATE CONSIDERED  <i>November 10, 2005</i>			
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>							

~~Sheet 1 of 24~~

101747.865

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: <del>101747.865</del>	
<b>LIST OF PRIOR ART CITED BY APPLICANT</b>  (Use several sheets if necessary)				APPLICANT(S): Benjamin OSHLACK et al.			
				FILING DATE: December 29, 2003		GROUP: 1614	
<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	HA						
	HB						
	HC						
	HD						
	HE						
	HF						
	HG						
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
	HH						
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
<i>JR</i>	HI	Glatt, William, M.D. FACP, "A New Method for Detoxifying Opioid-Dependent Patients"; J. Substance Abuse Treatment (1999) Vol.17, No.3, pp. 193-197					
<i>JR</i>	HJ	Gold, et al. "Rapid Opioid Detoxification During General Anesthesia"; Anesthesiology (1999) Vol 91, No 6, pp. 1639-1647.					
<i>JR</i>	HK	Greenwald, et al., "Comparative Clinical Pharmacology of Short-Acting $\mu$ Opioids in Drug Abusers"; J. Pharm and Exper Thera (1996) Vol 277, No 3, pp. 1228-1236.					
<i>JR</i>	HL	Gupta, et al., "Morphine Combined with Doxapram or Naloxone"; Anesthesia (1974) Vol 29, pp. 33-39.					
<i>JR</i>	HM	Richter et al., "Clinical Investigation on the Development of Dependence during Oral Therapy with Tramadol"; Arznieim-Forsch/Drug Res. 35 (No II)(1985)pp. 1742-1744.					
<i>JR</i>	HN	Rosen et al., "The effect of Lamotrigine on Naloxone-precipitated Opiate withdrawal"; Drug and Alcohol Dependence (1998) Vol 52, pp. 173-176.					
<i>JR</i>	HO	Rosen et al., "A Pilot Study of Dextromethorphan in Naloxone-Precipitated Opiate Withdrawal"; European J. of Pharm. (1996) Vol 307, pp. 251-257.					
EXAMINER  <i>Jeffrey E. Russel</i>				DATE CONSIDERED  <i>November 10, 2005</i>			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

~~Sheet 9 of 24~~

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: <del>10/827,623</del> 10/797,865	
<b>LIST OF PRIOR ART CITED BY APPLICANT</b>  (Use several sheets if necessary)				APPLICANT(S): Benjamin OSHLACK et al.			
				FILING DATE: December 29, 2003		GROUP: 1614	
<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	IA						
	IB						
	IC						
	ID						
	IE						
	IF						
	IG						
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
	IH						
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
JR	IJ	Schuh et al., "Buprenorphine, Morphine and Naloxone Effects during Ascending Morphine Maintenance in Humans"; J. Pharm and Exper Thera (1996) Vol 278, 2, pp. 836-846.					
JR	IK	Schuh et al., "Onset, Magnitude and Duration of Opioid Blockade Produced by Buprenorphine and Naltrexone in Humans"; Psychopharmacology (1999) Vol 145, pp. 162-174.					
JR	IL	Stevens et al., "Nonspecific Excitatory Effects of Morphine: Reverse-Order Precipitated Withdrawal and Dose-Dose Interactions"; Psychopharmacology (1981) Vol 75, pp. 210-211.					
JR	IM	Stine et al., "Reduction of Opiate Withdrawal-like Symptoms by Cocaine Abuse during Methadone and Buprenorphine Maintenance"; Am. J. Drug and Alcohol Abuse (1994) Vol 20, 4, pp. 445-458.					
JR	IN	Stine et al., "Use of Drug Combinations in Treatment of Opioid Withdrawal"; J. Clinical Psych. (1992) Vol 12, No 3, pp. 203-209.					
JR	IO	Stoller et al., "Effects of buprenorphine/naloxone in opioid-dependent humans" Psychopharmacology (2001) Vol 154, pp. 230-242.					
JR	IP	Strain et al., "Acute Effects of Buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers"; J. Pharm and Exper Thera (1992) Vol 261, No 3, pp. 985-993.					
JR	IQ	Strain et al., "Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers"; Psychopharmacology (2000) Vol 148, pp. 374-383.					
JR	IR	Strain et al., "Precipitated Withdrawal by Pentazocine in Methadone-Maintained Volunteers"; J. Pharm and Exper Thera (1993) Vol 267, No 2, pp. 624-634.					
JR	IS	Tai, et al., "Naltrexone: An Antagonist Therapy for Heroin Addiction"; NIDA (1997) 5 pages					
EXAMINER  Jeffrey E. Russel				DATE CONSIDERED  November 10, 2005			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: <del>10/037,603</del> 10/747,865	
<b>LIST OF PRIOR ART CITED BY APPLICANT</b>  (Use several sheets if necessary)				APPLICANT(S): Benjamin OSHLACK et al.			
				FILING DATE: December 29, 2003		GROUP: 1614	
<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	JA						
	JB						
	JC						
	JD						
	JE						
	JF						
	JG						
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
	JH						
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
<i>JR</i>	JI	Umbrecht et al., "Naltrexone shortened opioid detoxification with buprenorphine"; Drug and Alcohol Dependence (1999) Vol 56 pp. 181-190					
<i>JR</i>	JK	Vaccarino et al., "Enogenous Opiates: 1999"; Peptides 21 (2000) pp. 1975-2034.					
<i>JR</i>	JL	Wang et al., "Inverse Agonists and neutral antagonists at $\mu$ opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence"; J. Neurochemistry (2001) Vol 77, pp. 1590-1600.					
<i>JR</i>	JM	Way et al., "Responsivity to Naloxone during Morphine Dependence"; Annals New York Academy of Sciences, pp. 252-261 (Not listed)					
<i>JR</i>	JN	Weinberg et al., "Sublingual absorption of selected opioid analgesics"; Clin Pharm Thera (1988) Vol 44, No 3, pp. 335-342.					
<i>JR</i>	JO	Wells, et al., "In vivo Pharmacological Characterization of SoRI 9409, a Nonpeptidic Opioid $\mu$ -Agonist/ $\delta$ -Antagonist that Produces Limited Antinociceptive Tolerance and Attenuates Morphine Physical Dependence"; J. Pharm and Exper Thera (2001) Vol 297, No 2, pp. 597-605					
<i>JR</i>	JP	Wodak, Alex, "Drug Treatment for Opioid Dependence"; Australian Prescriber (2001) Vol 24, No 1, pp. 4-6.					
<i>JR</i>	JQ	Wright et al., "Acute physical dependence in Humans; repeated naloxone-precipitated withdrawal after a single-dose of methadone"; Drug and Alcohol Dependence (1991) Vol 27, pp. 139-148.					
<i>JR</i>	JR	Zhu et al., "Naltrexone-precipitated morphine withdrawal in infant rat is attenuated by acute administration if NOS inhibitors but not NMDA receptor antagonists"; Psychopharmacology (2000) Vol 150, pp. 325-336.					
EXAMINER <i>Jeffrey E. Risse</i>				DATE CONSIDERED <i>November 10, 2005</i>			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							



FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: <del>10/007,633</del> 10/777,865	
<b>LIST OF PRIOR ART CITED BY APPLICANT</b>  (Use several sheets if necessary)				APPLICANT(S): Benjamin OSHLACK et al.			
				FILING DATE: December 29, 2003		GROUP: 1614	
<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	KA						
	KB						
	KC						
	KD						
	KE						
	KF						
	KC						
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
	KH						
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
JR	KI	Han et al., "Mucocoadhesive buccal disks for novel nalbuphine prodrug controlled delivery; effect of formulation variable on drug release and mucoadhesive performance"; International J. Pharm (1999) Vol 177, pp. 201-209.					
JR	KJ	Handal et al., "Naloxone"; Annals of Emergency Medicine (1983) Vol 12:7, pp. 438-445.					
JR	KK	Harris et al., "Buprenorphine and Naloxone co-administration in opiate dependent patients stabilized on sublingual buprenorphine"; Drug and Alcohol Dependence (2000) Vol 61, pp. 85-94.					
JR	KL	Hawkes et al., "Effect of enteric-release formulation of naloxone on intestinal transit in volunteers taking codeine"; Aliment Pharm Ther (2001) Vol 15, pp. 625-630.					
JR	KM	Högger et al., "Comparison of tilidine/naloxone, tramadol and bromfenac in experimental pain: a double-blind randomized crossover study in healthy human volunteers"; International J. Clin Pharm and Thera (1999) Vol 37, No 8, pp. 377-385					
JR	KN	Budd, Keith, "Clinical Use of Opioid Antagonists"; Bailliere's Clinical Anesthesiology (1987) Vol 1, No 4, pp. 993-1011.					
JR	KO	Crain et al., "Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence: PNAS 92: 10540-10544 (11-1995)					
JR	KP	Howes et al., "The Pharmacology of TRS109, a new Narcotic Agonist/Antagonist Analgesic"; NIDA Research (1979) pp. 99-105.					
JR	KQ	Leeling et al., "Disposition and metabolism of codorphone in the rat, dog, and man"; Drug Metabolism and Disposition (1982) Vol 10, No 6, pp 649-653.					
EXAMINER <div style="font-size: 1.2em; font-family: cursive;">Jeffrey E. Russel</div>				DATE CONSIDERED <div style="font-size: 1.2em; font-family: cursive;">November 10, 2005</div>			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: <del>10/337,693</del> 10/777,865	
<b>LIST OF PRIOR ART CITED BY APPLICANT</b> (Use several sheets if necessary)				APPLICANT(S): Benjamin OSHLACK et al.			
				FILING DATE: December 29, 2003		GROUP: 1614	
<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	LA						
	LB						
	LC						
	LD						
	LE						
	LF						
	LG						
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
	LH						
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
jn	LI	Amass et al., "Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet"; Drug and Alcohol Dependence (2000) Vol 58, pp. 143-152.					
jn	LJ	Hassain et al., "Buccal and oral bioavailability of naloxone and naltrexone in rats"; (1987) Vol 36, pp. 127-130.					
jn	LK	Jasinski et al., "The human pharmacology and abuse potential of N-allylnoroxymorphone naloxone"; J. Pharm and Exper Thera (1967) Vol 157, No 2, pp. 420-426.					
jn	LM	Jones et al., "Nalmefene: blockade of intravenous morphine challenge effects in opioid abusers in humans"; Drug and Alcohol Dependence (2000) Vol 60, pp. 29-37.					
jn	LN	Kanof et al., "Clinical Characteristics of Naloxone-Precipitated Withdrawal in Human Opioid-Dependent Subjects"; J Pharma and Exper Thera (1992) Vol 260, No. 1, pp. 355-363.					
jn	LO	King et al., "Naltrexone Biotransformation and Incidence of Subjective Side Effects: A Preliminary Study"; Alcoholism: Clin and Exper Res (1997) Vol 21, No 5, pp. 906-909.					
jn	LP	Kogan et al., "Estimation of the Systemic Availability and Other Pharmacokinetic Parameters of Naltrexone in Man after Acute and Chronic Oral Administration"; Res. Comm. In Chem. Path. And Pharm (1977) Vol 18, No. 1, pp 29-34.					
jn	LQ	Kosten, Thomas R., M.D., "Buprenorphine for Benzodiazepine-Abusing Heroin Addicts"; Amer J of Psychiatry (1994) Vol 1, p 151.					
jn	LR	Kosten et al., "Opioid antagonist challenges in buprenorphine maintained patients"; Drug and Alcohol Dependence (1990) Vol 25, OO. 73-78.					
jn	LS	Kurland et al., "Naloxone and the Narcotic Abuser: A Controlled Study of Partial Blockade"; Inter. J. of the Addictions (1974) Vol 9, No 5, pp. 663-672.					
EXAMINER <i>Jeffrey E. Russell</i>				DATE CONSIDERED <i>November 10, 2005</i>			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: <del>10/827,623</del> 10/747,865	
<b>LIST OF PRIOR ART CITED BY APPLICANT</b>  (Use several sheets if necessary)				APPLICANT(S): Benjamin OSHLACK et al.			
				FILING DATE: December 29, 2003		GROUP: 1614	
<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	MA						
	MB						
	MG						
	MD						
	ME						
	MF						
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
	MG						
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
JR	MH	Lee et al., "Nalbuphine Coadministered with Morphine Prevents Tolerance and Dependence"; Anesth Analg (1997) Vol 84, pp.810-815					
JR	MI	Lehman, et al., "Influence of Naloxone on the Postoperative Analgesic and Respiratory effects of Buprenorphine"; Eur. J. Clin Pharm (1988) Vol 34, pp. 343-352.					
JR	MJ	Levine et al., "Potentiation of Pentazocine Analgesia by Low-dose Naloxone"; J Clin Invest (1988) Vol 82, pp. 1574-1577.					
JR	MK	Loimer et al., "Combined Naloxone/Methadone Preparations for Opiate Substitution Therapy"; J. of Substance Abuse Treatment (1991) Vol 8, pp. 157-160.					
JR	ML	Martin et al. "Bioavailability Investigation of a New Tilidine/Naloxone Liquid Formulation Compared to a Reference Formulation"; Arzneim-Forsch./Drug Res. (1999) Vol 49, pp. 599-607.					
JR	MM	Martin et al., "Demonstration of Tolerance to and Physical Dependence on N-allynmorphine (Nalorphine)"; J. Of Pharm and Exper Thera (1965) Vol 150, No 3. Pp. 437-442.					
JR	MN	Mendelson et al., "Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine stabilized, opiate-dependent volunteers"; Psychopharmacology (1999) Vol 141, pp. 37-46.					
JR	MO	Mendelson et al., "Buprenorphine and naloxone Interactions in Methadone Maintenance Patients"; Society of Biological Psychiatry (1997) Vol 41, pp. 1095-1101.					
JR	MP	Nutt et al., "Methadone-naloxone mixture for use in methadone maintenance programs"; Clin Pharm and Ther. Vol 15, No 2., pp 156-166 (Not dated)					
EXAMINER <u>Jeffrey E. Russell</u>				DATE CONSIDERED <u>November 10, 2005</u>			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: <del>10777,633</del> 10/777,865	
<b>LIST OF PRIOR ART CITED BY APPLICANT</b>  (Use several sheets if necessary)				APPLICANT(S): Benjamin OSHLACK et al.			
				FILING DATE: December 29, 2003		GROUP: 1614	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	NA						
	NB						
	NC						
	ND						
	NE						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
	NF						
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
JR	NG	Parwartikar et al., "Methadone-naloxone in combination for the Treatment of Heroin Addicts"; Clin. Pharm and Thera, Vol 14, No. 6, pp 941-948. <i>(not dated)</i>					
JR	NH	Parwartikar et al., "Naloxone-Methadone Combination for the Treatment of Opiate Dependence"; Missouri Institute of Psychiatry, pp. 1350-1354. <i>(not dated)</i>					
JR	NI	Pitts et al., "Antinociceptive and Response Rate-Altering Effects of Kappa Opioid Agonists, Spiradoline, Enadoline and U69,593, Alone and in Combination with Opioid Antagonists in Squirrel Monkeys"; J of Pharm and Exper Thera (1994) Vol 271, No 3, pp. 1501-1508.					
JR	NJ	Preston et al., "Buprenorphine and Naloxone alone and in combination in Opioid-dependant Humans"; Psychopharmacology (1988), Vol 94, pp. 484-490.					
JR	NK	Preston et al., "Differential Naltrexone Antagonism of Hydromorphone and Pentazocine Effects in Human Volunteers"; J of Pharm and Exper Thera (1993) Vol 264, No 2 pp. 813-823.					
JR	NJ	Preston et al., "Effects of Sublingually given naloxone in Opioid -dependant human volunteers"; Drug and Alcohol Dependence (1990) Vol 25, pp. 27-34.					
JR	NM	Bigelow et al., "Abuse Liability and Assessment of Buprenorphine-Naloxone Combinations"; Dept of Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine, pp. 145-149. <i>(not dated)</i>					
JR	NN	Wikler et al., "N-Allylnormorphine: Effects of single dose and Precipitation of Acute "Abstinence Syndromes" during addiction to morphine, methadone or heroin in man (post addicts)"; N-Allylnormorphine During Narcoctic Addiction (1953) pp. 8-20.					
EXAMINER  Jeffrey E. Russel				DATE CONSIDERED  November 10, 2005			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: <del>10/837,623</del> 10/747,865	
<b>LIST OF PRIOR ART CITED BY APPLICANT</b> (Use several sheets if necessary)				APPLICANT(S): Benjamin OSHLACK et al.			
				FILING DATE: December 29, 2003		GROUP: 1614	
<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	OA						
	OB						
	OC						
	OD						
	OE						
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
	OF						
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
	OG	Zaks et al., "Naloxone Treatment of Opiate Dependence"; JAMA (1971) Vol 215, No 13, pp. 2108-2110.					
	OH	Barton, et al., "Intranasal Administration of Naloxone by Paramedics"; Prehospital Emergency Care (2002) Vol 6, No 1, pp. 54-58.					
	OI	Blachly, Paul, H., M.D., "Naloxone in Opiate Addiction"; Current Psychiatric Therapies (1976) pp. 209-213.					
	OJ	Bashaw et al., "Relative bioavailability of controlled-release oral morphine sulfate during naltrexone blockade"; Inter J of Clin Pharm and Thera (1995) Vol 33, No 9, 524-529.					
	OK	Jasinski, D.R., "Assessment of the Abuse Potential of Morphinelike Drugs (Methods Used in Man)"; Drug Addiction (1977) pp. 197-258.					
	OL	Johnson et al., "Buprenorphine and Naloxone for Heroin Dependence"; Substance Use Disorders (2000) pp. 519-526.					
	OM	Strain et al., "Opioid antagonist effects of dezocine in opioid-dependent humans"; Clin Pharm and Thera (1996) Vol 60, No 2, pp. 206-217.					
	ON	Preston et al., "Abuse liability and studies of opioid agonist-antagonists in humans"; Drug and Alcohol Dependence (1991) vol 28, pp. 49-82.					
	OO	Brennscheidt et al., "Pharmacokinetics of Nortilidine and Naloxone after Administration of Tilidine/Naloxone Solution or Tilidine/Naloxone Sustained Release Tablets"; Arzneim-Forsch/Drug Rcs. (2000) Vol 50, pp. 1015-1022.					
EXAMINER  Jeffrey E. Russel				DATE CONSIDERED  November 10, 2005			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: <del>10/322,623</del> 10/777,865	
<b>LIST OF PRIOR ART CITED BY APPLICANT</b> (Use several sheets if necessary)				APPLICANT(S): Benjamin OSHLACK et al.			
				FILING DATE: December 29, 2003		GROUP: 1614	
<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	RA						
	RB						
	RC						
	RD						
	RE						
	RF						
	RG						
	RH						
	RI						
	RJ						
	RK						
	RL						
	RM						
	RN						
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
	RO						
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
	RP						
	RQ	Physician's Desk Reference (2001) see Revia, pp. 1146-1149 and Oxycontin, pp. 2697-2701					
	RR						
	RS						
EXAMINER				DATE CONSIDERED			
Jeffrey E. Russel				November 10, 2005			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							